MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Evaluating Clinical Practices of General Neurologists and Movement Disorder Specialists Based on 2020 AAN Parkinson Disease Quality Metrics

    C. Marshall, P. Vaswani (Philadelphia, USA)

    Objective: To evaluate and compare clinical practices of providers caring for patients with Parkinson’s disease utilizing searchable proxies of published quality metrics. Background: In 2020,…
  • 2024 International Congress

    Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques

    M. Bradbury, M. Aumann, D. Claassen, D. Finkelstein (Newark, USA)

    Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…
  • 2024 International Congress

    The Effect of Stochastic Resonance Stimulation in Neural Control of Balance During Walking in Parkinson Disease

    E. Alsaqabi, S. Dibianca, A. Sansare, K. Verma, J. Jeka, H. Reimann (Newark, USA)

    Objective: This study aimed to investigate the effect of stochastic resonance (SR) stimulation on balance control during visually perturbed walking in people with Parkinson disease…
  • 2024 International Congress

    Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.

    T. Guttuso, JR., R. Shepherd (Williamsville, USA)

    Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…
  • 2024 International Congress

    Parkinson’s Disease (PD) and predictors of Driving Cessation: Results from a 6-year Longitudinal Study and a systematic review of the literature

    P. Stamatelos, P. Hatzaki, I. Beratis, D. Pavlou, N. Andronas, E. Stanitsa, S. Fragkiadaki, D. Kontaxopoulou, A. Bonakis, A. Economou, G. Yannis, L. Stefanis, S. Papageorgiou (Athens, Greece)

    Objective: We sought to identify predictors of driving cessation among PD patients. Background: Motor and cognitive impairment of PD patients interfere with their driving ability.…
  • 2024 International Congress

    The Impact of VPS35 D620N Mutation on Alternative Autophagy and its Reversal by Estrogen in Parkinson’s Disease

    T. Shiraishi, K. Bono, Y. Iguchi, H. Okano (Minato-ku, Japan)

    Objective: We investigated the relationship between alternative autophagy and VPS35 D620N mutant-related PD pathogenesis. Background: VPS35 is critically involved in the mechanisms of neurodegeneration observed…
  • 2024 International Congress

    Writing rehabilitation in parkinson’s disease (pd) through a virtual workshop

    F. Echeverria, P. Sanchez Diaz, S. Revellini, G. Costa, G. Ziegler, S. Rodriguez Quiroga, T. Arakaki, N. Garretto (Buenos Aires, Argentina)

    Objective: Evaluate the effect of intensive writing training through a virtual workshop once a week and the potential influence in the quality of life in…
  • 2024 International Congress

    ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain

    Z. Zamfirov, D. Mugan, G. Ahluwalia (Annapolis, USA)

    Objective: The objective of this case report is to highlight the effect of a new technology, Evoked Compound Action Potential (ECAP) controlled closed-loop spinal cord…
  • 2024 International Congress

    Alpha-synuclein affects PRMT5-mediated cytoprotective pathway in neuronally differentiated SH-SY5Y cell

    T. Nakamura, N. Sugeno, T. Hasegawa, K. Ikeda, S. Yoshida, S. Ishiyama, K. Sato, A. Takeda, M. Aoki (Sendai, Japan)

    Objective: To explore the impact of α-synuclein (αS) on PRMT5. Background: Alpha-synuclein (αS) is recognized as the pivotal molecule in the pathomechanism of Parkinson's disease.…
  • 2024 International Congress

    Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease

    Z. Wang, R. Gomeni, R. Pahwa, R. Hauser, A. Formella, M. Grall, H. Upadhyaya, J. Rubin (Rockville, USA)

    Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…
  • « Previous Page
  • 1
  • …
  • 139
  • 140
  • 141
  • 142
  • 143
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley